SCHEMBL250027

SCHEMBL250027

CC(C)(C)NC(CO)c1ccc(O)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.46
ADRB2 P07550 10/20 0.46
ADRB1 P08588 1/20 0.44
HSD17B10 Q99714 1/20 0.37
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
TTR P02766 1/20 0.33
BACE1 P56817 1/20 0.33
ESRRB O95718 1/20 0.33
ESRRG P62508 1/20 0.33
CHRNA1 P02708 1/20 0.33
CHRNG P07510 1/20 0.33
CHRNB1 P11230 1/20 0.33
CHRNB2 P17787 1/20 0.33
SLC6A2 P23975 1/20 0.33
CHRNB4 P30926 1/20 0.33
SLC6A4 P31645 1/20 0.33
CHRNA3 P32297 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7191968 0.79 ADRB2 (0.53) ADRB2ADRB1SLC6A2SLC6A4
Meluadrine SCHEMBL120043 0.72 ADRB2 (0.65) ESR1ADRB2ADRB1SLC6A2SLC6A4
Meluadrine SCHEMBL29508537 0.72 ADRB2 (0.65) ESR1ADRB2ADRB1SLC6A2SLC6A4
Meluadrine SCHEMBL250026 0.72 ADRB2 (0.65) ESR1ADRB2ADRB1SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL6473077 0.71 ADRB2 (0.50) ESR1ADRB2ADRB1SLC6A2SLC6A3
SCHEMBL8469426 0.69 ADRB2 (0.51) ADRB2ADRB1
SCHEMBL5592508 0.69 PDK1 (0.38) ESR1HSD17B10PDK1PDK2PDK3
SCHEMBL4627723 0.69 ADRB1 (0.49) ESR1ADRB2ADRB1SLC6A2SLC6A4
SCHEMBL69021 0.68 ESR1 (0.63) ESR1HSD17B10TTR
SCHEMBL30234474 0.68 ESR1 (0.63) ESR1HSD17B10TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3131582-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES Vertex Pharmaceuticals Incorporated (US) 2017-02-22 EP disclosed
WO-2015160787-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-10-22 WO disclosed
EP-2651932-A1 BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-10-23 EP disclosed
EP-2651891-A1 BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-10-23 EP disclosed
WO-2012080457-A1 BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 WO disclosed
WO-2012080456-A1 BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 WO disclosed
EP-2401275-A1 NOVEL BRONCHODILATING DIAZAHETEROARYLS Respiratorius AB (SE) 2012-01-04 EP disclosed
WO-2010097410-A1 NOVEL BRONCHODILATING DIAZAHETEROARYLS RESPIRATORIUS AB (SE) 2010-09-02 WO disclosed
WO-2007011290-A1 Bronchorelaxing agents based on indol- and isoquinoline derivatives RESPIRATORIUS AB (SE) 2007-01-25 WO disclosed